Preventive Antibiotics for Tuberculosis Lower Risk of Death for People with HIV

Increased screening for tuberculosis (TB) and prophylactic treatment with isoniazid significantly reduced the incidence of active TB disease as well as mortality among patients treated at HIV clinics in Brazil, according to a study published in the August 14, 2013, advance edition of Lancet Infectious Diseases. This is the first evidence that a community-wide effort can prevent people coinfected with HIV and TB from developing active TB disease.

Read more:

CROI 2013: Researchers Look at Neurological Complications among People with HIV

Data from a small, yet well-designed trial to evaluate whether particular antiretroviral therapy (ART) regimens penetrate the central nervous system (CNS) and enhance neurocognitive performance were among several interesting findings regarding neurological complications among people with HIV presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta. Another study looked at similarities between Alzheimer's disease and neurocognitive impairment in people with HIV.

Read more:

Exercise Linked to Less Cognitive Impairment Among People with HIV

HIV positive people who recently engaged in physical exercise were about half as likely to show signs of neurocognitive impairment -- including impaired working memory and slower information processing -- as those who did not, according to a study published in the August 10, 2013, advance edition of the Journal of Neurovirology.

Read more:

CROI 2013: Statins for People with HIV -- How Sweet Is It?

Statins may help reduce co-morbid conditions such as cardiovascular disease and lower mortality for some people with HIV, but with a possible trade-off of higher diabetes risk, according to a series of studies presented and discussed at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.

Read more:

IAS 2013: People with HIV Who Use Statins May Have Lower Cancer Risk

HIV positive people who use statins to manage high cholesterol also may reduce their risk of developing non-AIDS-defining malignancies, according to study findings reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

Read more:

CROI 2013: HIV and Aging -- Are People with HIV at Greater Risk for Heart Disease and Cancer? [VIDEO]

Keri Althoff from the VA Medical Center and George Washington University Medical School described findings from a study looking at risk of non-AIDS conditions such as cardiovascular disease and cancer at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.

Read more:

IAS 2013: End-Stage Kidney Disease Is More Common Among People with HIV

HIV positive people in the U.S. and Canada are nearly 4 times as likely to develop end-stage renal disease than HIV negative people in the general population, largely driven by a very high rate among blacks, researchers reported last month at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

Read more:

CROI 2013: HIV+ Men at Increased Risk for Co-morbid Conditions Regardless of Age

 Men with HIV in a large cohort of U.S. veterans were more likely to develop cardiovascular disease, end-stage kidney disease, and certain cancers compared with HIV negative people, but not at earlier ages, according to a report presented at the 20th Conference on Retroviruses and Opportunistic Infections this month in Atlanta.

Read more:

FDA Limits Use of Oral Antifungal Ketoconazole Due to Side Effects and Drug Interactions

The antifungal drug ketoconazole (brand name Nizoral), used to treat certain AIDS-related opportunistic infections, should no longer be used as first-line oral therapy for any infection due to its potential to cause liver toxicity and adrenal gland problems, and instead should be reserved for those who cannot take or do not respond to other treatments, according to the U.S. Food and Drug Administration. The warning does not apply to topical formulations.

Read more:

CROI 2013: Heart Disease Rises Only Slighter Faster with Age for People with HIV

The risk of cardiovascular disease among HIV positive men in D:A:D rose from age 40-45 to 60-65, but only slightly more rapidly than in the general population,researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta. A related analysis found that the likelihood of death after a heart attack has fallen over time.

Read more:

IAS 2013: Studies Look at Second-Line Bone Changes, Fractures, and HIV- and HCV-Related Bone Loss

People with HIV experience less bone loss if they switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Other studies showed that HIV infection is associated with increased risk of hip fractures and shed light on different mechanisms of bone loss associated with HIV and hepatitis C.

Read more:

CROI 2013: HIV+ People Less Likely to Use Aspirin to Prevent Heart Attacks, and May Benefit Less [VIDEO]

People with HIV were less likely than HIV negative people to use daily aspirin to prevent heart attacks, but among those who did, aspirin did not appear to reduce the risk of myocardial infarction (MI), researchers reported last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Read more:

IAS 2013: Second-line HIV Therapy with NRTIs Linked to Bone Loss [VIDEO]

Bone loss occurs less often when people on failing antiretroviral therapy switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

Read more:

CROI 2013: Cancer Incidence After Starting Antiretroviral Therapy [VIDEO]

Rates of AIDS-related cancers start to fall not long after initiation of antiretroviral therapy (ART), but non-AIDS cancers rise with increasing time on therapy, according to study findings presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

Read more:

Coverage of the 2013 International AIDS Society Conference

HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.

Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.

Full listing by topic

HIVandHepatitis.com IAS 2013 conference section

7/6/13

Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.

Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.

Full listing by topic

HIVandHepatitis.com CROI 2013 conference section

3/4/13

Bone Loss and Fracture Risk are 'Modest' among HIV+ People, Linked to Tenofovir, Smoking, and HCV

Continued bone loss among HIV positive men with osteopenia was modest overall, but about 25% of those taking tenofovir (Viread, also in 4 antiretroviral coformulations) experienced significant loss, according to a recent study. A related meta-analysis found that HIV infection is associated with a modest likelihood of new fractures, with smoking and hepatitis C virus (HCV) coinfection further increasing the risk.

Read more:

CROI 2013: Retrovirus Conference Starts Sunday in Atlanta

The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.

Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.

Read more:

CROI 2013: Random Anal Biopsies Improve Detection of Pre-cancerous Lesions

Performing random anal biopsies increases the rate of diagnosis of high-grade squamous intraepithelial lesions (HSIL) during high-resolution anoscopy, researchers from Mt. Sinai School of Medicine in New York City reported at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013).

Read more:

HIV Infection May Raise Risk of Sudden Hearing Loss

Young HIV positive people age 18 to 35 had more than twice the likelihood of sudden sensorineural hearing loss compared with their HIV negative counterparts, according to an analysis of nearly 9000 people with HIV described in the February 21, 2013, advance online edition of JAMA Otolaryngology-Head & Neck Surgery.

Read more: